Efficacy of Deucravacitinib in Psoriatic Arthritis: A systematic Review and Meta-Analysis of Randomised Controlled Trials

This systematic review and meta-analysis aims to evaluate the efficacy of deucravacitinib 6 mg once daily compared with placebo in patients with active psoriatic arthritis. The primary outcome is the ACR20 response at week 16, with ACR50, ACR70, and PASI75 as secondary outcomes. Eligible randomized controlled trials will be reviewed, and relevant data will be extracted and synthesized quantitatively where appropriate. Risk of bias will be assessed using the Cochrane RoB 2 tool. The review aims to provide a reliable summary of the available evidence on the short-term joint and skin efficacy of deucravacitinib and identify limitations in the current evidence.